Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene. Issue 7 (21st March 2015)

• Record Type: Journal Article
• Authors: Mirelman, Anat; Alcalay, Roy N.; Saunders‐Pullman, Rachel; Yasinovsky, Kira; Thaler, Avner; Gurevich, Tanya; Mejia‐Santana, Helen; Raymond, Deborah; Gana‐Weisz, Mali; Bar‐Shira, Anat; Ozelius, Laurie; Clark, Lorraine; Orr‐Urtreger, Avi; Bressman, Susan; Marder, Karen; Giladi, Nir; the LRRK2 AJ consortium
• Is Part Of: Movement disorders. Volume 30:Issue 7(2015)
• Page Start: 981
• Page End: 986
• Publication Date: 2015-03-21
• Subjects: Movement disorders -- Periodicals; 610
• DOI: 10.1002/mds.26213
• Languages: English
• ISSNs: 0885-3185

Abstract

<abstract abstract-type="main"> <title>ABSTRACT</title> <sec id="mds26213-sec-0001" sec-type="section"> <title>Background</title> <p>The asymptomatic carriers of the Leucine rich repeat kinase 2 (<italic>LRRK2)</italic> G2019S mutation represent a population at risk for developing PD. The aim of this study was to assess differences in nonmotor symptoms between nonmanifesting carriers and noncarriers of the G2019S mutation.</p> </sec> <sec id="mds26213-sec-0002" sec-type="section"> <title>Methods</title> <p>Two hundred fifty‐three subjects participated in this observational cross‐sectional multicenter study. Standard questionnaires assessing anxiety, depression, cognition, smell, nonmotor symptoms, and rapid eye movement (REM) sleep behavior were administered. Analyses were adjusted for age, sex, family relations, education, and site.</p> </sec> <sec id="mds26213-sec-0003" sec-type="section"> <title>Results</title> <p>One hundred thirty‐four carriers were identified. Carriers had higher nonmotor symptoms score on the Nonmotor symptoms (NMS) questionnaire (<italic>P</italic> = 0.02). These findings were amplified in carriers older than age 50 y, with higher nonmotor symptoms scores and trait anxiety scores (<italic>P</italic> < 0.03).</p> </sec> <sec id="mds26213-sec-0004" sec-type="section"> <title>Conclusions</title> <p>In this cross‐section study, carriers of the G2019S <italic>LRRK2</italic> mutation endorsed subtle nonmotor symptoms. Whether these are early features of PD will require a longitudinal study. © 2015 International Parkinson and Movement Disorder Society</p> </sec> </abstract>